跳至主要内容
临床试验/NCT00478530
NCT00478530已完成不适用

The Effect of Intravitreal Avastin on the Retina Measured by Electroretinogram

Sheba Medical Center1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2007年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
1
主要终点
electroretinogram responses

研究概览

简要总结

To evaluate the scotopic and photopic ERG responses before and after one month of intravitreal avastin injection in patients with choroidal neovascularization.

A positive finding that will reveal a toxic effect of intravitreal avastin injection on any component of the retina will have a significant important clinical impact regarding the decision whether the benefit of avastin treatment for CNV will prevail over toxic effect.

详细描述

The study will include 20 patients who are diagnosed with CNV and were submitted for intravitreal injection of avastin. Patients with uncontrolled glaucoma, any ocular operation two months prior to the injection, ocular inflammatory disease, systemic hypertension treated with more than one medication, myocardial infarct, congestive heart disease will not be included in the study. After the patient will approve to participate in the study and will fall in with the inclusion and exclusion criteria, the patient will sign a written consent statement (enclosed).

Medical history and ophthalmic examination will be written in the study file. The patients will undergo the full-field ERG test using the ISCEV Protocol. Since the ERG is a non invasive test the patient will be admitted on the same day for intravitreal avastin in the designated eye. After one month the patient will undergo identical ERG protocol in addition to the standard follow-up examinations protocol for intravitreal avastin injection (1 day, 1 week, 1 month). The other eye will serve as control group.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients who were diagnosed with CNV caused by ARMD
  • •ERG can be performed in both eyes

排除标准

  • •Treatment within 7 days with VERTOPROFIN
  • •Treatment within one month with laser photocoagulation
  • •Ocular surgery for AMD (besides laser).
  • •Participation in other medical study
  • •Sub-fovea RPE atrophy in the study eye.
  • •CNV with ocular histoplasmosis, trauma, pathological myopia.
  • •Uveitis or history of uveitis.
  • •Retinal pigment epithelium tear in the fovea of the injected eye.
  • •Vitreous hemorrhage
  • •Conjunctivitis, keratitis, scleritis, endophthalmitis.
  • •Intraocular surgery (including cataract) within two months
  • •Uncontrolled glaucoma (IOP≥30 mmHg under glaucoma medications)
  • •Hypertension treated with two or more medication
  • •History of myocardial infarct
  • •History of myocardial insufficiency -

结局指标

主要结局

electroretinogram responses

时间窗: before treatment and one month after treatment

次要结局

未报告次要终点

研究者

申办方类型
Other Gov

研究点 (1)

Loading locations...

相似试验